PregLem In-Licenses Merck Serona's Jun Kinase Inhibitor

08/17/10 PregLem SA is in-licensing an oral, preclinical Jun kinase inhibitor, bentamapimod (AS602801), from Merck Serono SA, for prevention of postsurgical abdominal adhesions and endometriosis in patients.

+

-

 

Merck Serono to present Erbitux data at ESMO Congress

10/05/10 Merck Serono, a division of Merck KGaA, Darmstadt, Germany announces today that it will be presenting new data from several studies of Erbitux (cetuximab) in a range of solid tumor types including the first Phase II data in breast and prostate cancers. These data will be presented at the forthcoming 35th European Society for Medical Oncology Congress (ESMO) in Milan, October 8-12, 2010.

+

-

 

Merck submits Erbitux indication extension to EMA for NSCLC treatment

03/30/11 Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an indication extension to the European Medicines Agency for the approval of Erbitux in combination with standard 1st line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer with high epidermal growth factor receptor expression.

+

-